

# **Grey Wolf Animal Health Corp.**

Interim Condensed Consolidated Financial Statements  
(Unaudited)

**September 30, 2025**

**Grey Wolf Animal Health Corp.**  
Interim Condensed Consolidated Statements of Financial Position

	September 30, 2025 \$	December 31, 2024 \$
<b>Assets</b>		
<b>Current assets</b>		
Cash	6,749,871	6,410,747
Trade and other receivables	3,213,503	2,211,150
Inventories (note 6)	6,075,525	5,476,269
Prepaid expenses	524,899	415,567
Total current assets	<u>16,563,798</u>	<u>14,513,733</u>
<b>Non-current assets</b>		
Property and equipment (note 7)	6,307,549	6,606,559
Right-of-use assets (note 8)	506,009	691,500
Goodwill and intangible assets (note 9)	41,242,948	42,539,198
Deferred tax assets	819,889	1,251,188
Total non-current assets	<u>48,876,395</u>	<u>51,088,445</u>
<b>Total assets</b>	<u>65,440,193</u>	<u>65,602,178</u>
<b>Liabilities</b>		
<b>Current liabilities</b>		
Accounts payable and accrued liabilities	4,202,466	3,994,595
Income taxes payable	228,304	35,099
Borrowings (note 10)	2,145,493	2,067,031
Lease liabilities (note 8)	130,563	78,222
Total current liabilities	<u>6,706,826</u>	<u>6,174,947</u>
<b>Non-current liabilities</b>		
Borrowings (note 10)	23,373,300	24,804,209
Provisions (note 8)	342,910	-
Lease liabilities (note 8)	57,378	650,794
Deferred tax liabilities	4,749,837	5,141,067
Total non-current liabilities	<u>28,523,425</u>	<u>30,596,070</u>
<b>Total liabilities</b>	<u>35,230,251</u>	<u>36,771,017</u>
<b>Equity</b>		
Share capital (note 11)	31,528,598	31,528,598
Warrants (note 12)	3,502,371	3,502,371
Contributed surplus	1,832,159	1,780,832
Deficit	(6,653,186)	(7,980,640)
<b>Total equity</b>	<u>30,209,942</u>	<u>28,831,161</u>
<b>Total equity and liabilities</b>	<u>65,440,193</u>	<u>65,602,178</u>

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

# Grey Wolf Animal Health Corp.

## Interim Condensed Consolidated Statements of Income and Comprehensive Income

	Three months ended September 30,		Nine months ended September 30,	
	2025 \$	2024 \$	2025 \$	2024 \$
<b>Revenue</b> (note 5)	9,337,130	6,899,201	26,782,565	20,142,780
<b>Cost of sales</b>	4,420,080	3,390,910	12,383,510	9,744,199
<b>Gross profit</b>	4,917,050	3,508,291	14,399,055	10,398,581
<b>Expenses</b>				
Sales and marketing (note 14)	1,068,726	903,454	3,335,182	3,101,130
General and administrative (note 14)	1,513,344	1,067,413	4,551,585	3,110,165
Distribution (note 14)	560,664	403,330	1,641,144	1,189,019
Regulatory (note 14)	49,391	37,747	133,525	81,591
Depreciation and amortization (notes 7, 8 and 9)	475,441	258,691	1,453,878	774,313
Share-based compensation (note 13)	17,109	35,465	51,327	45,589
	3,684,675	2,706,100	11,166,641	8,301,807
	1,232,375	802,191	3,232,414	2,096,774
<b>Other (income) expense</b>				
Interest income	(24,267)	(52,766)	(81,829)	(156,614)
Interest expense	407,879	133,450	1,327,673	410,354
Foreign exchange loss (gain)	19,500	(6,124)	18,720	32,314
	403,112	74,560	1,264,564	286,054
<b>Income before income taxes</b>	829,263	727,631	1,967,850	1,810,720
<b>Current income tax expense</b>	170,246	128,182	600,326	384,947
<b>Deferred income tax expense</b>	110,041	97,298	40,070	220,003
	280,287	225,480	640,396	604,950
<b>Net income and comprehensive income for the period</b>	548,976	502,151	1,327,454	1,205,770
<b>Basic and diluted earnings per share for the period</b> (note 16)	0.02	0.02	0.04	0.04

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

# Grey Wolf Animal Health Corp.

## Interim Condensed Consolidated Statements of Changes in Shareholders' Equity

	Nine months ended September 30, 2025					
	Number of shares	Share capital \$	Warrants \$	Contributed surplus \$	Deficit \$	Total \$
<b>Balance – Beginning of period</b>	34,192,334	31,528,598	3,502,371	1,780,832	(7,980,640)	28,831,161
Net income for the period	-	-	-	-	1,327,454	1,327,454
Share-based compensation expense	-	-	-	51,327	-	51,327
<b>Balance – End of period</b>	<b>34,192,334</b>	<b>31,528,598</b>	<b>3,502,371</b>	<b>1,832,159</b>	<b>(6,653,186)</b>	<b>30,209,942</b>

	Nine months ended September 30, 2024					
	Number of shares	Share capital \$	Warrants \$	Contributed surplus \$	Deficit \$	Total \$
<b>Balance – Beginning of period</b>	31,032,222	28,577,293	3,502,371	1,695,198	(8,685,308)	25,089,554
Net income for the period	-	-	-	-	1,205,770	1,205,770
Share-based compensation expense	-	-	-	45,589	-	45,589
<b>Balance – End of period</b>	<b>31,032,222</b>	<b>28,577,293</b>	<b>3,502,371</b>	<b>1,740,787</b>	<b>(7,479,538)</b>	<b>26,340,913</b>

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

# Grey Wolf Animal Health Corp.

## Interim Condensed Consolidated Statements of Cash Flows

	Nine months ended September 30,	
	2025 \$	2024 \$
<b>Cash provided by (used in)</b>		
<b>Operating activities</b>		
Net income for the period	1,327,454	1,205,770
Adjustments to reconcile net income for the period to net cash flows		
Depreciation of property and equipment (note 7)	593,527	233,656
Depreciation of right-of-use assets (note 8)	107,580	65,790
Amortization of intangible assets (note 9)	1,296,250	731,250
Amortization of financing fees	117,829	92,267
Interest (income) expense (notes 8 and 10)	(66,383)	(5,696)
Share-based compensation expense (note 13)	51,327	45,589
Income tax expense	640,396	604,950
Income tax paid	(407,122)	(464,830)
Working capital changes		
Trade and other receivables	(1,002,353)	(826,640)
Inventories	(599,256)	56,276
Prepaid expenses	(109,332)	(88,782)
Accounts payable and accrued liabilities	316,066	(1,174,760)
	<u>2,265,983</u>	<u>474,840</u>
<b>Investing activities</b>		
Purchase of property and equipment (note 7)	<u>(402,712)</u>	<u>(351,971)</u>
<b>Financing activities</b>		
Repayment of borrowings (note 10)	(1,421,172)	(762,898)
Payment of principal portion of lease liabilities (note 8)	<u>(102,975)</u>	<u>(79,253)</u>
	<u>(1,524,147)</u>	<u>(842,151)</u>
<b>Increase (decrease) in cash during the period</b>	339,124	(719,282)
<b>Cash – Beginning of period</b>	<u>6,410,747</u>	<u>7,784,777</u>
<b>Cash – End of period</b>	<u>6,749,871</u>	<u>7,065,495</u>
<b>Supplementary information</b>		
Interest paid	1,276,226	323,784
Purchases of property and equipment included in accounts payable and accrued liabilities	31,001	110,155

The accompanying notes are an integral part of these interim condensed consolidated financial statements.

# Grey Wolf Animal Health Corp.

## Notes to Interim Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2025

---

### 1 Nature of operations

Grey Wolf Animal Health Corp. and its subsidiaries (the Company) was incorporated under the Business Corporations Act (Ontario) on February 9, 2021, as Magen Ventures I Inc. (Magen) and was classified as a capital pool company as defined, pursuant to Policy 2.4 of the TSX Venture Exchange (the Exchange).

On November 15, 2022, the Company closed its qualifying transaction (the Magen Transaction) with Grey Wolf Animal Health Inc. (GWAH).

In connection with the Magen Transaction, Magen changed its name to Grey Wolf Animal Health Corp. and consolidated its common shares prior to the completion of the Magen Transaction on the basis of one post-consolidation common share for every 16.6667 pre-consolidation common shares. Following these changes, GWAH amalgamated with 1000348459 Ontario Inc., a wholly owned subsidiary of Magen formed solely for the purpose of facilitating the Magen Transaction. Pursuant to the amalgamation, the shareholders of GWAH received one common share of the Company for each common share of GWAH. As a result of the Magen Transaction, GWAH is now legally a wholly owned subsidiary of the Company.

The primary focus of the Company's corporate strategy is to source, in-licence, acquire or compound branded and generic products for sale in both animal and human health markets in Canada.

The Company's head office is located at 333 Bay St., Suite 5100, Adelaide – West Tower, Toronto, Ontario, M5H 2R2.

### 2 Basis of presentation

The Company prepares its interim condensed consolidated financial statements in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (IFRS Accounting Standards) applicable to the preparation of interim condensed consolidated financial statements, including International Accounting Standard 34, Interim Financial Reporting. These interim condensed consolidated financial statements are presented in Canadian dollars and should be read in conjunction with the Company's consolidated financial statements for the year ended December 31, 2024, which were prepared in accordance with IFRS Accounting Standards.

The interim condensed consolidated financial statements have been prepared using the accrual basis of accounting.

The fair values of cash, trade and other receivables, accounts payable and accrued liabilities and lease liabilities approximate their carrying values due to their relatively short periods to maturity. The fair value of borrowings as at September 30, 2025 was \$24,760,314 (December 31, 2024 – \$26,712,686) and was determined using inputs from quoted market prices.

These interim condensed consolidated financial statements were approved by the Board of Directors on November 19, 2025.

# Grey Wolf Animal Health Corp.

## Notes to Interim Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2025

---

### 3 Summary of significant accounting policies

The accounting policies adopted in the preparation of these interim condensed consolidated financial statements are consistent with those followed in the preparation of the Company's consolidated financial statements for the year ended December 31, 2024.

#### Accounting pronouncements issued but not yet effective

The International Accounting Standards Board has issued classification, measurement and disclosure amendments to IFRS 9, Financial Instruments and IFRS 7, Financial Instruments Disclosures, with an effective date for annual reporting periods beginning on or after January 1, 2026. The amendments clarify the date of recognition and derecognition of some financial assets and liabilities and introduce a new exception for some financial liabilities settled through an electronic payment system. Other changes include a clarification of the requirements when assessing whether a financial asset meets the solely payments of principal and interest criteria and new disclosures for certain instruments with contractual terms that can change cash flows (including instruments where cash flows changes are linked to environment, social or governance targets).

IFRS 18, Presentation and Disclosure in Financial Statements (IFRS 18) is a new standard that will provide new presentation and disclosure requirements and that will replace IAS 1. IFRS 18 introduces changes to the structure of the statements of income and comprehensive income, provides required disclosures in financial statements for certain profit or loss performance measures that are reported outside an entity's financial statements and provides enhanced principles on aggregation and disaggregation in financial statements. Many other existing principles in IAS 1 have been maintained. IFRS 18 is effective for years beginning on or after January 1, 2027.

The impact of the adoption of these pronouncements is currently being assessed.

### 4 Significant accounting judgments, estimates and assumptions

Application of accounting policies requires management to use estimates and judgments that can have significant effects on the revenue, expenses, comprehensive income, assets and liabilities recognized and disclosures made in the interim condensed consolidated financial statements.

Management's best estimates concerning the future are based on the facts and circumstances available at the time estimates are made. Management uses historical experience, general economic conditions and assumptions regarding probable future outcomes as the basis for determining estimates. Estimates and their underlying assumptions are reviewed periodically, and the effects of any changes are recognized immediately. Actual results could differ from the estimates used.

There have been no material changes to the nature of estimates and judgments reported in the Company's consolidated financial statements for the year ended December 31, 2024.

# Grey Wolf Animal Health Corp.

## Notes to Interim Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2025

---

### 5 Revenue

The Company recognizes revenue on sale of products, commissions and other revenue in the interim condensed consolidated financial statements. All revenue is generated in Canada. The total revenue recognized in these categories is as follows:

	Three months ended September 30,		Nine months ended September 30,	
	2025 \$	2024 \$	2025 \$	2024 \$
Types of revenue				
Pharmaceutical, nutraceutical and consumable products	3,015,047	2,767,681	8,392,426	8,059,811
Compounded pharmaceutical products	5,730,363	3,759,380	16,970,140	10,903,889
Commissions and other revenue	591,720	372,140	1,419,999	1,179,080
Total revenue	9,337,130	6,899,201	26,782,565	20,142,780

### 6 Inventories

	September 30, 2025 \$	December 31, 2024 \$
Raw materials	2,068,548	1,406,453
Finished goods	4,031,977	4,103,816
Inventory reserve	(25,000)	(34,000)
	6,075,525	5,476,269

The cost of inventory recognized as an expense and included in the interim condensed consolidated statements of income and comprehensive income as part of cost of sales was \$3,281,583 and \$9,218,237 for the three and nine months ended September 30, 2025 (2024 – \$2,663,400 and \$7,625,139).

# Grey Wolf Animal Health Corp.

## Notes to Interim Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2025

### 7 Property and equipment

	Land \$	Buildings \$	Office furniture and equipment \$	Computer equipment and software \$	Lab equipment \$	Leasehold improvements \$	Total \$
<b>Cost</b>							
As at December 31, 2024	490,000	4,390,000	253,496	231,315	776,136	1,522,990	7,663,937
Additions	-	-	10,211	92,852	153,747	37,707	294,517
As at September 30, 2025	490,000	4,390,000	263,707	324,167	929,883	1,560,697	7,958,454
<b>Depreciation and impairment</b>							
As at December 31, 2024	-	5,647	49,751	100,607	165,925	735,448	1,057,378
Depreciation	-	197,296	31,294	32,378	148,014	184,545	593,527
As at September 30, 2025	-	202,943	81,045	132,985	313,939	919,993	1,650,905
<b>Net book value</b>							
December 31, 2024	490,000	4,384,353	203,745	130,708	610,211	787,542	6,606,559
September 30, 2025	490,000	4,187,057	182,662	191,182	615,944	640,704	6,307,549

Depreciation included in cost of sales for the three and nine months ended September 30, 2025 was \$15,168 and \$446,626 (2024 – \$69,082 and \$198,816).

### 8 Leases

The Company has lease contracts for property. One property lease has an initial term of three years with an extension option. The second property lease has an initial term of two years with an extension option. Management exercises judgment in determining whether these extension options are reasonably certain to be exercised and has not included these extension options in the calculation of the lease liabilities and right-of-use assets. The rental payments for the property lease extensions will be adjusted at the time of extension based on the market rate as at that date.

On July 30, 2025, the Company signed a new office lease in Oakville, Ontario. The lease term commences November 1, 2025. Over the initial term of the lease of three years, the total minimum lease payments are \$155,000. The Company also has a renewal option for an additional period of three years.

On August 22, 2025, the Company signed a new facility lease in Ancaster, Ontario. The lease term commences January 1, 2027. Over the initial term of the lease of 15 years, the total minimum lease payments are \$7,884,000. The Company also has a renewal option for an additional period of ten years, based on two options of five years each. Following the signing of this lease, it was no longer reasonably certain that extension options in existing leases would be exercised.

# Grey Wolf Animal Health Corp.

## Notes to Interim Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2025

---

Set out below are the carrying amounts of right-of-use assets recognized and the movements during the period:

	\$
<b>As at December 31, 2024</b>	691,500
Removal of extension options	(418,940)
Change in decommissioning costs	341,029
Depreciation expense	<u>(107,580)</u>
<b>As at September 30, 2025</b>	<u>506,009</u>

Depreciation included in cost of sales for the three and nine months ended September 30, 2025 was \$43,973 and \$96,852 (2024 – \$19,189 and \$57,567).

The decommissioning liability for certain leases is included within provisions on the interim condensed consolidated statements of financial position.

Set out below are the carrying amounts of lease liabilities and the movements during the period:

	\$
<b>As at December 31, 2024</b>	729,016
Removal of extension options	(459,989)
Payments	(102,975)
Accretion of interest	<u>21,889</u>
<b>As at September 30, 2025</b>	<u>187,941</u>

A breakdown of the current and non-current portion of lease liabilities is as follows:

	September 30, 2025	December 31, 2024
	\$	\$
Current lease liabilities	130,563	78,222
Non-current lease liabilities	<u>57,378</u>	<u>650,794</u>
	<u>187,941</u>	<u>729,016</u>

# Grey Wolf Animal Health Corp.

## Notes to Interim Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2025

### 9 Goodwill and intangible assets

Goodwill and intangible assets of the Company consist of the following:

	Goodwill \$	Customer relationships \$	Non-compet agreement \$	Brand \$	Pre-1954 Charter \$	Total \$
<b>Cost</b>						
As at December 31, 2024	24,202,255	15,660,000	1,000,000	2,700,000	2,300,000	45,862,255
As at September 30, 2025	24,202,255	15,660,000	1,000,000	2,700,000	2,300,000	45,862,255
<b>Amortization and impairment</b>						
As at December 31, 2024	-	3,299,223	23,834	-	-	3,323,057
Amortization	-	1,153,417	142,833	-	-	1,296,250
As at September 30, 2025	-	4,452,640	166,667	-	-	4,619,307
<b>Net book value</b>						
As at December 31, 2024	24,202,255	12,360,777	976,166	2,700,000	2,300,000	42,539,198
As at September 30, 2025	24,202,255	11,207,360	833,333	2,700,000	2,300,000	41,242,948

### 10 Borrowings

A summary of the movements in borrowings is as follows:

	CWB credit loan \$	CWB CPM credit loan \$	CWB mortgage \$	Total borrowings \$
<b>Balance – December 31, 2024</b>	8,242,526	14,248,407	4,380,307	26,871,240
Repayment of borrowings	(800,174)	(574,271)	(46,727)	(1,421,172)
Interest and accretion expense	344,289	761,606	239,056	1,344,951
Interest paid	(286,508)	(754,631)	(235,087)	(1,276,226)
<b>Balance – September 30, 2025</b>	7,500,133	13,681,111	4,337,549	25,518,793
Current borrowings	1,142,476	907,429	95,588	2,145,493
Non-current borrowings	6,357,657	12,773,682	4,241,961	23,373,300
	7,500,133	13,681,111	4,337,549	25,518,793

# Grey Wolf Animal Health Corp.

## Notes to Interim Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2025

### 11 Share capital

Authorized

Unlimited number of common shares without par value

Issued and outstanding

	Number of shares	
	September 30, 2025	December 31, 2024
Common shares	34,192,334	34,192,334

### 12 Warrants

The Company issued warrants to compensate third party brokers for transaction costs incurred directly in relation to the issuance of common shares prior to completion of the Magen Transaction.

A summary of outstanding warrants is as follows:

Issuance/related issuance	Number of common share entitlements	Exercise price \$	Expiry date	Fair value at initial recognition \$
2021 broker warrants	192,000	1.67	June 17, 2026	181,440
			<b>Broker warrants</b>	<b>Total warrants</b>
<b>Balance as at December 31, 2024</b>			192,000	192,000
<b>Balance as at September 30, 2025</b>			192,000	192,000

### 13 Share-based compensation

The Company has established a stock option plan for its directors, officers, employees and consultants under which the Company may grant options from time to time to acquire a maximum of 10% of the issued and outstanding common shares. The exercise price of each option granted under the plan shall be determined by the Board of Directors.

Options may be granted for a maximum term of ten years from the date of the grant. They are non-transferable and are exercisable as determined by the Board of Directors when the option is granted.

Share-based compensation expense for the three and nine months ended September 30, 2025 was \$17,109 and \$51,327 (2024 – \$35,465 and \$45,589).

# Grey Wolf Animal Health Corp.

## Notes to Interim Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2025

A summary of the stock option changes during the nine months ended September 30, 2025 and the total number of stock options outstanding as at that date is set forth below:

	Number of stock options	Weighted average exercise price \$
<b>Balance as at January 1, 2025</b>	2,243,500	1.27
Forfeited	(15,000)	2.00
<b>Balance as at September 30, 2025</b>	<u>2,228,500</u>	<u>1.27</u>

The following table summarizes information about the stock options outstanding as at September 30, 2025.

Exercise price \$	Number of stock options	Weighted average remaining contractual life in years	Number of outstanding options exercisable
0.73	240,000	8.55	80,001
0.83	300,000	0.40	300,000
0.88	345,000	1.55	345,000
1.30	520,000	3.21	520,000
1.50	418,500	5.50	418,500
1.67	60,000	0.72	60,000
2.00	345,000	7.13	230,001
	<u>2,228,500</u>	<u>3.87</u>	<u>1,953,502</u>

### 14 Nature of expenses

	Three months ended September 30,		Nine months ended September 30,	
	2025 \$	2024 \$	2025 \$	2024 \$
<b>Sales and marketing</b>				
Salary, bonus, benefits	767,556	540,512	2,320,506	2,123,357
Travel, meals, business expenses	85,192	81,753	219,920	243,541
Professional and outside services	96,198	97,790	297,931	279,378
Advertising and promotion	88,626	102,349	293,311	289,701
Other expenses	31,154	81,050	203,514	165,153
Total sales and marketing	<u>1,068,726</u>	<u>903,454</u>	<u>3,335,182</u>	<u>3,101,130</u>

# Grey Wolf Animal Health Corp.

## Notes to Interim Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2025

	Three months ended September 30,		Nine months ended September 30,	
	2025	2024	2025	2024
	\$	\$	\$	\$
<b>General and administrative</b>				
Salary, bonus, benefits	761,493	566,570	2,401,237	1,663,021
Travel, meals, business expenses	17,742	4,406	73,666	26,315
Professional and outside services	363,501	274,551	1,071,995	797,414
Other expenses	370,608	221,886	1,004,687	623,415
Total general and administrative	1,513,344	1,067,413	4,551,585	3,110,165

	Three months ended September 30,		Nine months ended September 30,	
	2025	2024	2025	2024
	\$	\$	\$	\$
<b>Distribution</b>				
Salary, bonus, benefits	129,276	69,062	369,380	204,658
Travel, meals, business expenses	2,184	1,560	6,398	5,972
Professional and outside services	394	113	1,182	339
Other expenses	62,869	48,356	170,039	165,873
Freight expense	365,941	284,239	1,094,145	812,177
Total distribution	560,664	403,330	1,641,144	1,189,019

	Three months ended September 30,		Nine months ended September 30,	
	2025	2024	2025	2024
	\$	\$	\$	\$
<b>Regulatory</b>				
Professional and outside services	49,391	37,747	133,525	81,591

# Grey Wolf Animal Health Corp.

## Notes to Interim Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2025

---

### 15 Contingencies

#### Claims and legal actions

In the normal course of operations, the Company may be subject to litigation. When appropriate, management will record a provision while it actively pursues its position. When it is the opinion of management that the likelihood and measurability of the potential liability is not determinable, no provision will be recorded. As at September 30, 2025, \$nil was recorded in relation to legal claims (December 31, 2024 – \$nil).

#### Indemnifications

All directors and officers of the Company are indemnified by the Company for various items including, but not limited to, all costs to settle lawsuits or actions due to their association with the Company, subject to certain restrictions. The Company has purchased directors' and officers' liability insurance to mitigate the cost of any potential future lawsuits or actions. The term of the indemnification is not explicitly defined, but is limited to events for the period during which the indemnified party served as a director or officer of the Company. The maximum amount of any potential future payment cannot be reasonably estimated, but could have a material adverse effect on the Company.

The Company has also indemnified third parties in relation to certain debt and equity offerings and their respective affiliates and directors, officers, employees, shareholders, partners, advisers and agents and each other person, if any, controlling any of the third parties or their affiliates against certain liabilities.

### 16 Earnings per share

The following table shows the calculation of basic and diluted earnings per share:

	Three months ended September 30,		Nine months ended September 30,	
	2025 \$	2024 \$	2025 \$	2024 \$
Net income for the period	548,976	502,151	1,327,454	1,205,770
Weighted average number of common shares	34,192,334	31,032,222	34,192,334	31,032,222
Weighted average number of diluted common shares	35,597,334	31,032,222	35,597,334	31,032,222
Basic earnings per share	0.02	0.02	0.04	0.04
Diluted earnings per share	0.02	0.02	0.04	0.04

# Grey Wolf Animal Health Corp.

## Notes to Interim Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2025

---

### 17 Segment reporting

The Company has two reportable operating segments: the Animal Health business unit and the Pharmacy business unit. The chief operating decision maker for the Company comprises the Chief Executive Officer and the Board of Directors.

#### Animal Health business unit

The Animal Health business unit, which began activities in 2015 and grew as a result of the acquisition of Veterinary Healthcare Solutions Inc. in 2018, primarily focuses on selling, marketing and distributing pharmaceutical, nutraceutical and consumable products to veterinary clinics across Canada.

#### Pharmacy business unit

The Pharmacy business unit, which was acquired on completion of the Trutina Pharmacy Inc. and TruBalance Healthcare Inc. acquisition on September 1, 2021 and grew as a result of the 6303021 Manitoba Ltd. (The Compounding Pharmacy of Manitoba) acquisition on December 2, 2024, compounds pharmaceuticals for the human and animal health markets.

#### Corporate

The corporate cost centre represents certain centralized assets, liabilities and costs, including those associated with being a public reporting entity.

The following tables set forth items by reportable operating segment and corporate as at and for the three and nine months ended September 30, 2025 and 2024 and as at and for the year ended December 31, 2024.

	<b>Three months ended September 30, 2025</b>		
	<b>Animal Health</b>	<b>Pharmacy</b>	<b>Total</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>
Revenue	3,561,984	5,775,146	9,337,130
Cost of sales	1,548,565	2,871,515	4,420,080
Gross profit	2,013,419	2,903,631	4,917,050

# Grey Wolf Animal Health Corp.

## Notes to Interim Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2025

	<b>Three months ended September 30, 2024</b>		
	<b>Animal Health</b>	<b>Pharmacy</b>	<b>Total</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>
Revenue	3,110,070	3,789,131	6,899,201
Cost of sales	1,429,613	1,961,297	3,390,910
Gross profit	1,680,457	1,827,834	3,508,291

	<b>Nine months ended September 30, 2025</b>		
	<b>Animal Health</b>	<b>Pharmacy</b>	<b>Total</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>
Revenue	9,667,745	17,114,820	26,782,565
Cost of sales	4,387,728	7,995,782	12,383,510
Gross profit	5,280,017	9,119,038	14,399,055

	<b>Nine months ended September 30, 2024</b>		
	<b>Animal Health</b>	<b>Pharmacy</b>	<b>Total</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>
Revenue	9,166,157	10,976,623	20,142,780
Cost of sales	4,114,776	5,629,423	9,744,199
Gross profit	5,051,381	5,347,200	10,398,581

	<b>As at and for the nine months ended September 30, 2025</b>			
	<b>Animal Health</b>	<b>Pharmacy</b>	<b>Corporate</b>	<b>Total</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>
Total assets	11,678,546	52,257,722	1,503,925	65,440,193
Total liabilities	1,782,784	7,367,141	26,080,326	35,230,251
Property and equipment	38,330	6,259,867	9,352	6,307,549
Right-of-use assets	-	506,009	-	506,009
Goodwill and intangible assets	1,712,336	39,530,612	-	41,242,948
Additions to property and equipment and intangible assets	15,624	275,135	3,757	294,516
Depreciation and amortization	6,905	1,988,657	1,795	1,997,357

# Grey Wolf Animal Health Corp.

## Notes to Interim Condensed Consolidated Financial Statements

(Unaudited)

September 30, 2025

### As at and for the year ended December 31, 2024

	Animal Health \$	Pharmacy \$	Corporate \$	Total \$
Total assets	10,375,700	52,829,806	2,396,672	65,602,178
Total liabilities	1,624,354	7,484,406	27,662,257	36,771,017
Property and equipment	29,610	6,569,558	7,391	6,606,559
Right-of-use assets	-	691,500	-	691,500
Goodwill and intangible assets	1,712,336	40,826,862	-	42,539,198
Additions to property and equipment and intangible assets	7,891	634,006	7,367	649,264
Depreciation and amortization	9,214	1,517,055	2,065	1,528,334

### 18 Related party transactions

A shareholder of the Company holds 80,000 stock options, which were granted in 2018 and are fully vested.

#### Compensation of key management personnel

Key management includes the Company's directors and executive management team. The remuneration of directors and the senior management team was as follows:

	Three months ended September 30,		Nine months ended September 30,	
	2025 \$	2024 \$	2025 \$	2024 \$
Salary, benefits, director fees and bonus	393,345	298,361	1,196,364	917,846
Share-based compensation expense	14,070	12,695	38,893	125,016
	<u>407,415</u>	<u>311,056</u>	<u>1,235,257</u>	<u>1,042,862</u>